구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ledipasvir-Sofosbuvir |
Overview Company | Gilead Sciences |
Overview Modality | CGT |
Overview Target | Chronic Hepatitis C |
Overview Indication | Chronic Hepatitis C |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study.. To evaluate the efficacy and safety of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) in HCV-infected pediatric chronic kidney disease (CKD) patients on maintenance hemodialysis (HD). This is a single-center, prospective single-arm observational explora… |
Clinical Safety signal | Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study.. To evaluate the efficacy and safety of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) in HCV-infected pediatric chronic kidney disease (CKD) patients on maintenance hemodialysis (HD). This is a single-center, prospective single-arm observational explora… |
Clinical Result source | ClinicalTrials.gov NCT03423641 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03423641 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ledipasvir-Sofosbuvir |
Overview Company | Gilead Sciences |
Overview Modality | CGT |
Overview Target | Chronic Hepatitis C |
Overview Indication | Chronic Hepatitis C |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study.. To evaluate the efficacy and safety of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) in HCV-infected pediatric chronic kidney disease (CKD) patients on maintenance hemodialysis (HD). This is a single-center, prospective single-arm observational explora… |
Clinical Safety signal | Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study.. To evaluate the efficacy and safety of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) in HCV-infected pediatric chronic kidney disease (CKD) patients on maintenance hemodialysis (HD). This is a single-center, prospective single-arm observational explora… |
Clinical Result source | ClinicalTrials.gov NCT03423641 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03423641 |
추천 비교
추천 비교